The use of ciclosporin in psoriasis.

作者: John Berth‐Jones

DOI: 10.1080/09546630500423914

关键词:

摘要: Ciclosporin is a cyclic undecapeptide discovered in the 1970s to possess potent inhibitory action on T lymphocytes. The subsequent discovery, 1979, that it was remarkably effective treatment of psoriasis transformed thinking about nature disease, which subsequently became generally recognized as autoimmune nature. remains one most and rapidly acting treatments currently available for psoriasis. Virtually all diverse manifestations this disease can respond. main side effects are nephrotoxicity hypertension. There considerable variation between individuals susceptibility these so careful monitoring required. should be used single or intermittent short courses except severe cases safer than continuous treatment. rate improvement depends very much dose, ranges from 2 5.0 mg/kg/day. combined with any topical useful dose-sparing effect achieved way if patients compliant. In ciclosporin often combination other systemic antipsoriatic drugs order spare dose each agent reduce toxicity. Concurrent intercurrent use ultraviolet therapy discouraged due increased risk non-melanoma skin cancer. This article reviews mode action, pharmacokinetics, indications, contraindications, effects, dosage regimens, pretreatment screening monitoring, drug interactions, combinations management

参考文章(221)
Lotti T, Panconesi E, Bonan P, Plasminogen activation in psoriasis. Acta Dermato-venereologica. ,vol. 146, pp. 36- ,(1989)
Tagami H, Matsumura N, Saijo S, Takematsu H, Hashimoto K, Exanthematic type of pustular psoriasis consisting of two types of pustular lesion. Acta Dermato-venereologica. ,vol. 71, pp. 442- 444 ,(1991)
Bargman Jm, Lipscombe J, Lewis Gf, Cattran D, Deterioration in renal function associated with fibrate therapy. Clinical Nephrology. ,vol. 55, pp. 39- 44 ,(2001)
Kunzendorf U, Neumayer Hh, Schreiber M, Protective effects of calcium antagonists in human renal transplantation. Kidney International. ,vol. 36, ,(1992)
G Thiel, T Rufli, A Bock, M Spöndlin, F P Brunner, M Mihatsch, J Landmann, Long-term benefits and risks of cyclosporin A (sandimmun)--an analysis at 10 years. International congress on cyclosporine. ,vol. 26, pp. 2493- 2498 ,(1994)
Edgar A. Mueller, John M. Kovarik, Johannes B. van Bree, Joachim Grevel, Peter W. Lücker, Klaus Kutz, Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation Pharmaceutical Research. ,vol. 11, pp. 151- 155 ,(1994) , 10.1023/A:1018922517162
Dominique Teillac-Hamel, Yves de Prost, Christine Bodemer, Emmanuel Mahé, Anne Pruszkowski, Cyclosporine in childhood psoriasis. Archives of Dermatology. ,vol. 137, pp. 1532- 1533 ,(2001)
J.I. Harper, I. Ahmed, G. Barclay, M. Lacour, P. Hoeger, M.J. Cork, A.Y. Finlay, N.J.E. Wilson, R.A.C. Graham-Brown, J.M. Sowden, A.L. Beard, M.J. Sumner, J. Berth-Jones, Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. British Journal of Dermatology. ,vol. 142, pp. 52- 58 ,(2000) , 10.1046/J.1365-2133.2000.03241.X